Establishing a genetic diagnosis in these families is also important for future generations, as drug treatment trials with new targeted therapies, such as BRD4780, are currently being developed as potential treatment targets for ADTKD-MUC1 and could benefit future generations of affected families [44]. This evidence concerns the gene MUC1 and autosomal dominant medullary cystic kidney disease with or without hyperuricemia.